Genmark Diagnostics (GNMK) 8.52 $GNMK GenMark

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genmark Diagnostics (GNMK) 8.52 $GNMK

GenMark Diagnostics Reports Q2 Financial Results
BusinessWire - Thu Jul 28, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2016.
GNMK: 8.52 (-0.12)

GenMark Diagnostics to Present at the 36th Annual Canaccord Genuity Growth Conference
BusinessWire - Wed Jul 27, 4:37PM CDT
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the 36th Annual Canaccord Genuity Growth Conference to be held in Boston, Massachusetts at the InterContinental Hotel on Wednesday, August 10, 2016 at 8:30 a.m. Eastern Time. The presentation will be made available at http://ir.genmarkdx.com.
GNMK: 8.52 (-0.12)

GenMark Achieves CE Mark for its ePlex(R) Sample-to-Answer System
BusinessWire - Wed Jun 08, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices Directive (98/79/EC) for its ePlex Instrument System and ePlex Respiratory Pathogen (RP) Panel.
GNMK: 8.52 (-0.12)

GenMark Diagnostics to Present at the William Blair 36th Annual Growth Stock Conference
BusinessWire - Mon Jun 06, 3:10PM CDT
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the William Blair 36th Annual Growth Stock Conference to be held in Chicago, Illinois at the Four Seasons Hotel on Wednesday, June 15, 2016 at 12:40 p.m. Central Time. The presentation will be made available at http://ir.genmarkdx.com.
GNMK: 8.52 (-0.12)

GenMark Reports First Quarter 2016 Results
BusinessWire - Tue May 03, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2016.
GNMK: 8.52 (-0.12)

GenMark Diagnostics Schedules First Quarter 2016 Financial Results Conference Call for May 3, 2016
BusinessWire - Tue Apr 19, 1:00PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 3, 2016. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 90864115 approximately five minutes prior to the start time.
GNMK: 8.52 (-0.12)

GenMark Announces Preliminary Q4 Financial Results and Initiation of ePlex(TM) Analytical Studies
BusinessWire - Tue Jan 12, 3:05PM CST
--- XT-8 Installed Base Grew by 17 to 633
GNMK: 8.52 (-0.12)

GenMark Diagnostics to Present at the 2016 J.P. Morgan Healthcare Conference
BusinessWire - Wed Dec 30, 12:05PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2016 J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, California on Wednesday, January 13, 2016. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 3:00 pm Pacific Time. The presentation will be made available at http://ir.genmarkdx.com/.
GNMK: 8.52 (-0.12), JPM: 67.50 (unch)

Healthcare Sector Equities in Motion -- Tetraphase Pharma, Cardiovascular Systems, Sagent Pharma, and GenMark Diagnostics
ACCESSWIRE - Mon Dec 21, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Park Lane Advisor has initiated coverage on the following equities: Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), Cardiovascular Systems Inc. (NASDAQ: CSII), Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), and GenMark Diagnostics Inc. (NASDAQ: GNMK). Free research report on Tetraphase Pharma can be accessed at http://www.parklaneadvisor.com/ On Friday, December 18, 2015, the NASDAQ Composite ended at 4,923.08, down 1.59%, the Dow Jones Industrial Average declined 2.10%, to finish the day at 17,128.55, and the S&P 500 closed at 2,005.55, down 1.78%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
GNMK: 8.52 (-0.12), TTPH: 3.80 (-0.08), CSII: 24.47 (-0.10), SGNT: 21.76 (+0.03)

Can The Uptrend Continue for GenMark (GNMK)?
Zacks Equity Research - Zacks Investment Research - Tue Dec 01, 7:54AM CST
Investors certainly have to be happy with GenMark Diagnostics, Inc. (GNMK) and its short term performance
GNMK: 8.52 (-0.12)

Lisa M.. Giles of GenMark Diagnostics, Inc. (GNMK)-NasdaqGM bought Shares of GNMK
M2 - Thu Nov 05, 8:14AM CST
Lisa M.. Giles, director of GenMark Diagnostics, Inc. (GNMK)-NasdaqGM bought 8,500 shares of GNMK from the open market on 2015-11-04. The stock was up 2.11% after the InsiderCow.com report.
GNMK: 8.52 (-0.12)

GenMark Diagnostics Schedules Third Quarter 2015 Financial Results Conference Call for October 27, 2015
BusinessWire - Thu Oct 15, 1:00PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Tuesday, October 27, 2015. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 62237999 approximately five minutes prior to the start time.
GNMK: 8.52 (-0.12)

BUYINS.NET: GNMK SqueezeTrigger Price is $10.35. There is $59,804,136 That Short Sellers Still Need To Cover.
M2 - Fri Sep 18, 12:19PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Genmark Diagnostics Inc (NASDAQ:GNMK) in real time and just received an alert that GNMK is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 5772600 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $10.35. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
GNMK: 8.52 (-0.12)

The Market for Prenatal, Newborn and Carrier Genetic Testing 2015
M2 - Fri Jul 24, 4:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7ccfb/the_market_for) has announced the addition of the "The Market for Prenatal, Newborn and Carrier Genetic Testing" report to their offering. The Market for Prenatal, Newborn and Carrier Genetic Testing discusses the technologies and tests used in chromosomal analysis and in the diagnosis of inherited disorders and the detection of carriers of inherited diseases. The growing number of genetic tests has been made possible by advances in technology, including advances in chromosomal analysis - from traditional karyotyping to fluorescence in situ hybridization (FISH), and then to chromosomal microarrays and next generation sequencing. Detection of single gene mutations has been made possible with FISH and polymerase chain reaction (PCR) technology, and is moving into even new possibilities with sequencing based tests that can evaluate large numbers of genes simultaneously. The recent introduction of noninvasive prenatal testing (NIPT) has made it possible to perform prenatal screening of fetuses without the need for invasive procedures. The growing global genetic testing laboratory services market is discussed, including: - Carrier testing - Prenatal testing - Newborn screening - Neonatal/pediatric testing - Testing for adult onset genetic disorders The technologies used for newborn screening discussed in the report include: - Karyotyping - Fluorescence in situ Hybridization - Chromosomal Microarrays - Polymerase Chain Reaction and Other Nucleic Acid Amplification Technologies - DNA Sequencing - Mass Spectrometry - Conventional versus Non-Invasive Prenatal Testing Inherited disease testing was already a large market, but the potential for rapid growth has attracted companies and investors. The report highlights recent activities in this rapidly evolving market. Leading competitors and product developers are listed in the manufacturer profiles. The profiled companies include: Partial List - 23andMe, Inc. - AB SCIEX (A Danaher Corporation Company) - Abbott Laboratories - Affymetrix, Inc. - Agena Bioscience Inc. - Agilent Technologies Inc. - Ambry Genetics Corp. - ARUP Laboratories - Astra Biotech GmbH - Asuragen, Inc. - Athena Diagnostics, Inc. (A Quest Diagnostics Business) - AutoGenomics, Inc. - Berry Genomics Co., Ltd. - BGI-Shenzhen - Bio-Rad Laboratories, Inc. - Bio-Reference Laboratories, Inc. (BRLI) - Centogene AG - Chromsystems Instruments & Chemicals GmbH - Claritas Genomics, Inc. - Color Genomics, Inc. - CombiMatrix Corporation - Counsyl, Inc. - Courtagen Life Sciences, Inc. - GenapSys - Gene by Gene, Ltd. - Genection, Inc. (An Invivoscribe Company) - GeneDx - GenePeeks, Inc. - Genesis Genetics - Genetadi Biotech S.L. - Genetic Technologies Limited / Phenogen Sciences, Inc. (U.S. Division) - GenMark Diagnostics, Inc. - Genoma Group - Genomed AG - GenPath / GenPath Women's Health For more information visit http://www.researchandmarkets.com/research/h7...market_for
GNMK: 8.52 (-0.12), ABT: 42.02 (-0.81), AGMX: (), BRLI: 34.69 (+0.08), A: 46.98 (-0.16), CBMX: 3.05 (-0.05), AFFX: 14.01 (+0.02), ATHN: 122.43 (-0.03)

U.S. and Global Molecular Diagnostics in Infectious Disease Testing Market Report (Updated Edition)
M2 - Wed Jul 22, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tj5pr3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics - along with the development of microarray devices to measure analytes in the blood - has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: - The existing and emerging technologies in the field - The U.S. and global market size for molecular diagnostic products - The profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE - Seegene - Siemens AG - SIRS-Lab - TrimGen - TrovaGene For more information visit http://www.researchandmarkets.com/research/tj5pr3/molecular
GNMK: 8.52 (-0.12), LIFE: 2.92 (-0.05), ABT: 42.02 (-0.81), MYGN: 20.36 (-0.18), AGMX: (), CPHD: 34.32 (-0.37), ILMN: 168.34 (-0.65), QGEN: 26.51 (-0.22), LMNX: 21.07 (+0.04)

GenMark Diagnostics Schedules Second Quarter 2015 Financial Results Conference Call for August 6, 2015
BusinessWire - Tue Jul 21, 3:05PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Thursday, August 6, 2015. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 87665468 approximately five minutes prior to the start time.
GNMK: 8.52 (-0.12)

Global Molecular Diagnostics in Infectious Disease Testing Market 2015
M2 - Thu May 07, 6:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l4xc2p/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics - along with the development of microarray devices to measure analytes in the blood - has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: - The existing and emerging technologies in the field - The U.S. and global market size for molecular diagnostic products - The profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE - Seegene - Siemens AG - SIRS-Lab - TrimGen - TrovaGene - Veredus Laboratories - Veridex, LLC For more information visit http://www.researchandmarkets.com/research/l4xc2p/molecular
GNMK: 8.52 (-0.12), LIFE: 2.92 (-0.05), ABT: 42.02 (-0.81), MYGN: 20.36 (-0.18), AGMX: (), CPHD: 34.32 (-0.37), ILMN: 168.34 (-0.65), QGEN: 26.51 (-0.22), LMNX: 21.07 (+0.04)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 154

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 65

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 22

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 17

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 101

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading

Top 5 Most Recently Viewed Articles

Volta Finance Limited: Monthly Insights and Performance Metrics

Updated Category News Views 252

Understanding Volta Finance Limited's Performance for September 2025 Volta Finance Limited (VTA / VTAS) recently released its monthly report for September 2025. This report sheds light on the performance metrics that have shaped the company's strategies and outcomes over the past month, illustrating how they navigate an ever-changing financial landscape. Performance...

Continue Reading
Class Actions Alert: Understanding Investor Rights for SOC, LMT, NVO, LINE

Updated Category News Views 213

Understanding Class Action Lawsuits for Shareholders In today’s fast-paced investment world, shareholders must stay informed about class action lawsuits that may affect their investments. A recent alert highlights key class actions involving four publicly-traded companies, offering investors a glimpse into their rights and potential next steps. Sable Offshore Corp....

Continue Reading
Exploring ONCT-534: New Insights on Advanced Prostate Cancer

Updated Category News Views 202

Recent Updates on ONCT-534 for Advanced Prostate Cancer Oncternal Therapeutics, Inc. (NASDAQ: ONCT) has unveiled encouraging updates regarding its investigational therapy, ONCT-534, specifically targeting relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). This exciting development stems from the company’s ongoing Phase 1/2 Study, known as...

Continue Reading
GDS Holdings Celebrates Successful IPO of C-REIT in Shanghai

Updated Category News Views 197

GDS Holdings Completes C-REIT IPO on Shanghai Stock Exchange Shanghai, China — GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698), a prominent developer and operator of high-performance data centers, has recently triumphantly finished its initial public offering (IPO) for the China REIT (C-REIT) on the Shanghai Stock Exchange. This achievement marks a significant milestone...

Continue Reading
Surge in Russian Stocks: MOEX Russia Index Reaches New Heights

Updated Category News Views 255

Russian Stocks Experience Notable Gains In recent trading sessions, Russian stocks showed significant upward movement, showcasing the resilience of various sectors within the economy. With the MOEX Russia Index closing higher, this is an indication of investor optimism and market recovery. Key Contributors to Market Gains Sector Performance Highlights The increase in the...

Continue Reading